Dr. Flühmann is a Pharmacist by training and holds a PhD in molecular biology from ETH Zürich, Switzerland on “Structural analysis and characterization of cell surface receptors” and a MBA of the University of St. Gallen Switzerland. He was working in various position in the field of pharmaceuticals and functional nutrition. Dr. Flühmann was leading a global multidisciplinary research and development team at Roche/DSM nutritional products developing novel compounds for the prevention and treatment of diabetes. At Vifor Pharma Ltd Dr. Flühmann was acting as Global Brand Director defining global strategic product plans across all functions (medical, marketing, market research, regulatory, life cycle management, logistics) and ensuring the operational execution. In his current position at Vifor Pharma Ltd Dr. Flühmann is Global Lead Non-Biological Complex Drugs with a main interest in regulatory aspects of nanomedicines. He is Steering Committee Member of the Non-Biological Complex Drugs Working Group hosted at Lygature a non for profit organization. The mission of the Non-Biological Complex Drugs Working Group is to work on appropriate and harmonized science-based approval and post-approval standards for Non-Biological Complex Drugs to ensure patient benefit and safety.
Regulatory aspects of nanomedicines, Non-Biological Complex Drugs, medical, marketing, market research, regulatory, life cycle management, logistics
Dr Rodica Olteanu , MD, PhD is a dermatologist and Medical Director of Colentina Clinical Hospital, Bucharest, Romania. She received her PhD on lupus research in 2007, in collaboration with Hamburg University. She is involved in autoimmunity and immunogenicity of biologics and biosimilars and published more than 100 papers in lupus and psoriasis. She is Alumni EADV Club rewarded, winner of many international grants, member in EADV Project Committee, AAD, GRAPPA, EuSCLE, SRD, ILDS member and member in Editorial Board of SRD and LAJPPA. She complete her educational training by participating at Master Class on Psoriasis- Barcelona, Center for Excellence in Psoriasis-Vienna, Pearls in Lisbon and Bucharest-as invited speaker and also at Harvard. She supports the idea of a collaborative work group of specialists in different aria for autoimmune diseases also with patient’s participation and she intent to create an Autoimmune Diseases Center in Colentina Hospital.
Abdeen Mustafa Omer (BSc, MSc, PhD) is an Associate Researcher at Energy Research Institute (ERI). He obtained both his PhD degree in the Built Environment and Master of Philosophy degree in Renewable Energy Technologies from the University of Nottingham. He is qualified Mechanical Engineer with a proven track record within the water industry and renewable energy technologies. He has been graduated from University of El Menoufia, Egypt, BSc in Mechanical Engineering. His previous experience involved being a member of the research team at the National Council for Research/Energy Research Institute in Sudan and working director of research and development for National Water Equipment Manufacturing Co. Ltd., Sudan. He has been listed in the book WHO'S WHO in the World 2005, 2006, 2007 and 2010. He has published over 300 papers in peer-reviewed journals, 200 review articles, 7 books and 150 chapters in books.
Renewable Energy Technologies
Renewable Energy Technologies
Gregory J. Glover, MD, a registered patent attorney and non-practicing physician with Pharmaceutical Law Group PC, is one of the nation’s experts on the complex interaction of food and drug laws and intellectual property, including the patent and non-patent provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”). Greg represents life sciences companies, investors, and trade associations on strategic product development issues, including market protection analyses based on intellectual property laws, FDA regulations, and patent portfolio evaluations. Greg has also testified on behalf of the research-based pharmaceutical industry before committees of both houses of Congress on legislative matters affecting market protection for pharmaceutical, biotechnology, and medical device products, and he has made presentations on behalf of research-based companies on market protection issues before the Food and Drug Administration, the Federal Trade Commission, and the Department of Justice. Greg received his A.B. in biochemical sciences from Harvard College and his JD from Harvard Law School. Following law school, he completed medical school at Duke University and served as an intern at New England Deaconess Hospital in Boston, MA.
Autoimmune Diseases, Dermatology, Medicine
Dr. Subashchandrabose Chinnathambi obtained his Ph.D. in Biochemistry from Max Planck Institute for Structural Molecular Biology (MPGASMB), Hamburg, Germany in 2011. He has examined the Influence of Phosphorylation on the Pathological Conformation of Human Microtubule-Associated Protein Tau in Alzheimer’s disease. His post-doctoral training at the German Center for Neurodegeneration Disease (DZNE)–Bonn and Max Planck Institute for Neurobiological Research-Cologne, Germany, studied the role of rare MAPT (p. A152T mutant) mutation increases the pathological conformation and physiological properties of Tau (axonal protein) in Alzheimer’s patient. After the post-doctoral stint he joined as a Scientist at the Biochemical Sciences Division, National Chemical Laboratory (CSIR-NCL). In last three years, he established a neurobiology research group at CSIR-NCL; he is currently focusing on signaling cascades and post-translational modifications of Tau (Alzheimer’s) and Alpha Synuclein (Parkinson’s) disease. He has expertise in the area of neurochemistry and especially on Alzheimer’s disease
Renewable Energy Technologies